The Top 5 Biosimilar Articles for the Week of April 11

Video

Here are the top 5 biosimilar articles for the week of April 11, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of April 11, 2022.

Number 5: White bagging is wreaking havoc for patients and creates liability issues for hospital pharmacies, according to experts who appeared on a panel during the National Comprehensive Cancer Network (NCCN) annual meeting, which was held in a virtual format.

Number 4: Julie M. Reed, the executive director of the Biosimilars Forum, called for policies to support adoption of lower-cost biologics.

Number 3: A real-world analysis found similar safety and efficacy profiles between a biosimilar ranibizumab (Razumab) and the reference product (Lucentis, Accentrix) in Indian patients with diabetic macular edema.

Number 2: Switzerland-based company Fresenius Kabi announced that its pegfilgrastim biosimilar received marketing authorization in Europe and that it has obtained a majority stake in biosimilar manufacturer mAbxience and acquired its subsidiary.

Number 1: Republic of Korea-based Celltrion Healthcare launched its high-concentration adalimumab biosimilar in Canada and won several Brazilian tenders to supply its infliximab biosimilar.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
The Top 5 Biosimilar Articles for the Week of February 19, 2024.
Here are the top 5 biosimilar articles for the week of February 12, 2024.
Ha Kung Wong, JD
The top 5 biosimilar articles for the week of February 5, 2024.
The Top 5 Biosimilar Articles for the Week of January 29
Here are the top 5 biosimilar articles for the week of January 15, 2024.
The Top 5 Center for Biosimilars Articles for the Week of January 8, 2024.
Prerakkumar Parikh, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.